Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function.
Conagh J KellyMatthew ChuRossana UntaruBahador Assadi-KhansariDongqing ChenAmanda J CroftJohn D HorowitzAndrew J BoyleAaron L SverdlovDoan T M NgoPublished in: Journal of cardiovascular development and disease (2023)
Secreted frizzled-related protein 5 (SFRP5) is a novel anti-inflammatory adipokine that may play a role in cardiovascular development and disease. However, there is yet to be a comprehensive investigation into whether circulating SFRP5 can be a biomarker for cardiac function. Plasma SFRP5 levels were measured via ELISA in 262 patients admitted to a cardiology unit. Plasma SFRP5 levels were significantly lower in patients with a history of heart failure (HF), coronary artery disease (CAD), and atrial fibrillation (AF; p = 0.001). In univariate analyses, SFRP5 levels were also significantly positively correlated with left ventricular ejection fraction (LVEF) (r = 0.52, p < 0.001) and negatively correlated with E/E' (r = -0.30, p < 0.001). Patients with HF, CAD, low LVEF, low triglycerides, high CRP, and high eGFR were associated with lower SFRP5 levels independent of age, BMI, or diabetes after multivariate analysis (overall model r = 0.729, SE = 0.638). Our results show that low plasma SFRP5 levels are independently associated with the presence of HF, CAD, and, importantly, impaired LV function. These results suggest a potential role of SFRP5 as a biomarker, as well as a mediator of cardiac dysfunction independent of obesity and metabolic regulation.
Keyphrases
- coronary artery disease
- heart failure
- left ventricular
- atrial fibrillation
- ejection fraction
- type diabetes
- small cell lung cancer
- metabolic syndrome
- anti inflammatory
- adipose tissue
- insulin resistance
- acute heart failure
- acute myocardial infarction
- risk assessment
- weight gain
- catheter ablation
- high density
- data analysis
- glycemic control